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Abstract
Background
Low vitamin D levels have been associated with depressive symptoms in population-based
studies and non-clinical samples as well as with clinical depression. This study aimed to
examine the association of vitamin D levels with the severity and dimensions of depressive
symptoms in hospitalized patients with a current episode of depression taking into account
confounding variables.
Methods
We investigated 380 patients (mean age 47±12 years, 70% women) who were consecu-
tively hospitalized with a main diagnosis of an ICD-10 depressive episode. All patients self-
rated depressive symptom severity with the Hospital Anxiety and Depression Scale (HADS-
D), the Beck Depression Inventory-II (BDI-II), and the Brief Symptom Inventory. A principal
component analysis was performed with all 34 items of these questionnaires and serum lev-
els of 25-hydroxyvitamin D3 (25-OH D) were measured.
Results
Vitamin D deficiency (<50 nmol/l), insufficiency (50–75 nmol/l), and sufficiency (>75 nmol/l)
were present in 55.5%, 31.8% and 12.6%, respectively, of patients. Patients with vitamin D
deficiency scored higher on the HADS-D scale and on an anhedonia symptom factor than
those with insufficient (p-values0.023) or sufficient (p-values0.008) vitamin D. Vitamin
D deficient patients also scored higher on the BDI-II scale than those with sufficient vitamin
D (p = 0.007); BDI-II cognitive/affective symptoms, but not somatic/affective symptoms,
were higher in patients with vitamin D deficiency (p = 0.005) and insufficiency (p = 0.041)
relative to those with sufficient vitamin D. Effect sizes suggested clinically relevant findings.
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Conclusions
Low vitamin D levels are frequent in hospitalized patients with a current episode of depres-
sion. Especially 25-OH D levels <50 nmol/l were associated with cognitive/affective depres-
sive symptoms, and anhedonia symptoms in particular.
Introduction
Systematic reviews and meta-analyses of population-based cross-sectional and prospective
cohort studies have shown that low serum levels of 25-hydroxyvitamin D3 (25-OH D) are asso-
ciated with depressive symptoms and clinical depression, respectively [1,2]. Clinical Practice
Guidelines from the US Endocrine Society define vitamin D deficiency as 25-OH D less than
50 nmol/l, vitamin D insufficiency as 25-OH D between 50 and 75 nmol/l, and vitamin D suffi-
ciency as 25-OH D greater than 75 nmol/l [3]. However, it should be noted that the issue of
accepted clinical cut-offs for vitamin D deficiency is somewhat controversial; for instance, the
US Institute of Medicine report defines vitamin D deficiency as 25-OH D less than 40 nmol/l
[4]. With the cut-offs recommended by the US Endocrine Society applied to a national repre-
sentative sample of young adults, the odds ratio for a current depressive episode was 1.8-fold
higher in individuals with deficient vitamin D when compared to those with sufficient vitamin
D [5]. Moreover, vitamin D supplementation with at least 800 I.U. daily improves depression
to a similar extent as antidepressant medications [6] and vitamin D supplementation may aug-
ment the effect of antidepressants in patients with major depressive disorder [7]. Therefore,
there is now ample evidence for the assumption that vitamin D deficiency plays a role at least
in persons with clinically relevant depressive symptoms. Plausible neurobiological and neuro-
endocrine mechanisms have been proposed for this link, including a role of vitamin D in brain
areas processing depressive mood [8], in serotoninergic and dopaminergic function [9,10], and
in constraining systemic inflammation being associated with depression [11].
Surprisingly few studies have investigated the relation between vitamin D deficiency and
depressive symptom severity in patients with a psychiatric diagnosis of depression. One study
we could track showed increased scores for the Hamilton Depression Rating Scale in vitamin D
deficient outpatients with a major depressive disorder without psychosis, although no adjust-
ment was made for covariates [7]. This is crucial, because several risk factors for vitamin D
deficiency have been identified some of which are also associated with depression; these include
ageing, female sex, dark skin pigmentation, winter season, obesity, impaired liver function, no
use of vitamin D supplements, antidepressant and anticonvulsant medications, and psychiatric
comorbidity like anxiety and eating disorders [5,12–15]. A range of physical medical condi-
tions, including cardiovascular disease, liver disease and renal disease may also be associated
with low vitamin D levels [3,4].
To our knowledge, no study to date has examined a relation between vitamin D and the
severity of depressive symptoms in hospitalized patients with clinical depression. Such a rela-
tionship is of particular clinical importance because a need for hospitalization may indicate
more severe illness with ultimate implications of vitamin D deficiency for multicomponent
antidepressant treatment. This even more so, as antidepressant effects of vitamin D supple-
mentation can particularly be expected in patients with clinically significant depressive symp-
toms [16]. However, not all clinically depressed patients may have deficient or insufficient
vitamin D, so uncritical substitution may pose harm to those depressed patients with sufficient
vitamin D. For instance, the US Endocrine Society defines a safety margin to minimize the risk
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of hypercalcemia as 25-OH D equal to 250 nmol/l [3]. The US Institute of Medicine report
already raises concerns about potential adverse effects with 25-OH D equal to 125 nmol/l [4].
Side effects that may typically occur with 25-OH D levels above 375 nmol/l are hypercalcemia,
hypercalciuria, and hyperphosphatemia with the associated soft-tissue and vascular calcifica-
tions and nephrolithiasis in the long term [12]. Furthermore, clinical depression can also be
induced by hypercalcemia due to hypervitaminosis D [17].
Depression is a heterogeneous concept regarding its symptom dimensions with studies
showing that, for instance, cognitive, somatic, and neurovegetative depressive symptoms differ-
ently relate to a range of health outcomes, including biological ones [18–20]. A recent study
reported vitamin D deficiency or insufficiency to be associated with specific psychopathology
in schizophrenia patients, including grandiosity, social anhedonia and irregular speech [21].
Therefore, we also computed an exploratory principal component analysis using items from
three widely used self-rated depressive symptom scales to possibly identify depressive symptom
factors with a particularly strong relationship with vitamin D deficiency, which, to our knowl-
edge, has not previously been tested.
The aims and novel aspects of this study were to investigate the relationship between vita-
min D status and both the severity and dimension of depressive symptomatology in hospital-
ized patients with psychiatric depression applying three validated depressive symptom scales.
We specifically hypothesized that patients with a current depressive episode plus vitamin D
deficiency (<50 nmol/l) would show higher levels on depressive symptom scales, and possibly
depressive symptom factor scores, when compared with depressed patients with sufficient
(<75 nmol/l) and also insufficient (50–75 nmol/l) 25-OH D serum levels, even after adjust-
ment for important confounding variables of this relationship.
Materials and Methods
Study participants and design
The 380 patients who participated in this study were consecutively hospitalized between Janu-
ary 2012 and December 2014 with a primary diagnosis of an ICD-10 depressive episode with-
out psychosis at the Department of Psychosomatic Medicine, Clinic Barmelweid, Switzerland,
to undergo inpatient psychosomatic rehabilitation. Within the Swiss healthcare system, inpa-
tient rehabilitation for adults is legally covered by insurance granted that several eligibility cri-
teria are met. These include insufficient effectiveness of outpatient (psycho)therapy, a need for
distance from the family and/or job environment, functional impairment with insufficient
maintenance of activities of daily living and mobility, problem behaviors that cannot be con-
trolled by the patient (e.g., severe avoidance behavior), sustained inability to work or risk of
becoming disabled, and motivation and ability to participate in a multimodal (aka interdisci-
plinary or multicomponent) treatment program.
Fig 1 depicts the flowchart of the patient recruitment. Specific inclusion criteria were a main
diagnosis of a first-time or recurrent mild (F32.0/F33.0), moderate (F32.1/F33.1), severe
(F32.2/F33.2) or unspecified (F32.9/F33.9) depressive episode and complete data for psycho-
metric questionnaires and vitamin D status. For patients who, during the observation period,
were hospitalized more than once, we used data from the first hospitalization. Because of well-
known high rates of comorbidities in depressed inpatients, other mental disorders and physical
diseases were not exclusion criteria.
The diagnosis of a depressive episode, including its severity and recurrence, and of other
major psychiatric diagnoses and physical diseases were made by one medical coder based on
discharge reports prepared by a board-certified psychiatrist /psychosomatic medicine special-
ist. The medical coder has been certified by an accredited agency training coders to make
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ICD-10 diagnoses based on Swiss Diagnosis Related Groups (DRG), a system to classify hospi-
tal cases into groups for reimbursement, which became effective in January 2012. Moreover,
federal regulations (represented by the National Society for Quality Development in Hospitals)
require standardized assessments of demographic and psychometric data for quality control of
inpatient psychosomatic treatment. As part of clinical routine, a fasting morning chemistry
screening panel is done at hospital entry in virtually every patient, whereas vitamin D status
has increasingly been determined over the last years in our clinic, systematically so since 2014.
All psychometric and laboratory data were obtained within the first three days of the hospi-
talization and collected from hospital charts and electronic files retrospectively for the purpose
of this study between December 2014 and March 2015. All patients agreed their data could be
used for quality control of the inpatient treatment program. Patient records and information
was anonymized and de-identified prior to analysis. The Ethics Committee for Northwest/Cen-
tral Switzerland approved the study protocol.
Fig 1. Flow chart of the included 380 patients with a depressive episode.
doi:10.1371/journal.pone.0138550.g001
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Psychometric assessment
Wemeasured the severity of depressive symptoms with three self-rated instruments validated
in German. Patients received a personal login to complete web-based versions of question-
naires. Master level psychology students supervised by a clinical psychologist reviewed ques-
tionnaire data and encouraged patients to fill in items left blank, so to meet standards for
quality control required by federal regulations.
Hospital Anxiety and Depression Scale. The 7-item depression subscale of the Hospital
Anxiety and Depression scale (HADS-D) covers the severity of depressive symptoms in the
previous week [22,23] and has been widely used in psychiatric populations [24]. The items
exclude somatic/affective symptoms of depression to avoid any bias with symptoms from coex-
isting medical conditions. Each item is rated on a 4-point Likert scale ranging from 0 ("mostly")
to 3 ("not at all"), yielding a total score between 0 and 21. A score 8 defines the threshold for
clinically relevant depressive symptoms. In the current sample, Cronbach’s alpha was 0.82,
indicating good reliability of the HADS-D.
Beck Depression Inventory-II. The 21-item Beck Depression Inventory-II (BDI-II) cov-
ers the severity of depressive mood over the last two weeks, including today [25,26]. Each item
is scored with a value between 0 and 3, yielding a total score between 0 and 63. A score 14
defines the threshold for clinically relevant depressive symptoms. For clinical samples, the
BDI-II items can be divided into cognitive/affective and somatic/affective subscales, for
instance, based on the model by Beck et al [25]; the validity of these subscales has recently been
reevaluated [27]. In the current sample, Cronbach’s alpha was 0.91, indicating excellent reli-
ability of the BDI-II total score. The cognitive/affective and somatic/affective subscales showed
good reliabilities with a Cronbach's alpha of 0.88 and 0.84, respectively.
Brief Symptom Inventory. The 6-item depression subscale of the Brief Symptom Inven-
tory (BSI-D) covers the severity of depressive symptoms in the previous seven days [28,29].
The patients rated the intensity of each item on a 5-point Likert scale ranging from 0 ("not at
all") to 4 ("very strong"), yielding a total score between 0 and 24. In the current sample, Cron-
bach’s alpha was 0.84, indicating good reliability of the BSI-D.
Vitamin D status
Vitamin D (25-OH D) was measured in serum by certified commercial laboratories using liq-
uid chromatography-mass spectrometry between January 2012 and December 2013 and, start-
ing January 2014, using an enzyme-linked fluorescent assay. Lower limits of detection are 10
nmol/l for the first assay and 20.3 nmol/l for the second one. To account for the different tech-
niques, the applied vitamin D assay method was dummy coded and used as a covariate in the
multivariate analysis. Following previous guidelines for the definition of vitamin D status,
25-OH D concentrations>75 nmol/l were considered sufficient vitamin D. Levels between
50 and 75 nmol/l and<50 nmol/l of 25-OH D were defined insufficient and deficient vitamin
D levels, respectively [3].
Assessment of covariates
Age in years and sex were noted. Following the patients' regional origin, skin pigmentation
was dummy coded as dark (Southern and Eastern Europe) or light (Middle Europe) [30]. We
defined the six months with the least (November to April) and the most (May to October) sta-
tistical sunshine hours in Switzerland as winter and summer seasons, respectively [31]. Medical
staff measured height and weight with patients wearing light clothing. Obesity was defined by a
body mass index 30 kg/m2 and used as a covariate.
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To control for inflammatory processes, C-reactive protein levels were measured in serum
(C-reactive Protein (Latex), Cobas Integra 400 plus, Roche Diagnostics, Mannheim, Germany)
and dummy coded as normal (5 mg/L) or elevated (>5 mg/L). One missing value for C-reac-
tive protein was replaced by the sample mean. To account for insufficient production of vita-
min D due to any liver affection, catalytic activity of transaminases was determined in serum
(Cobas Integra). Activity of alanine aminotransferase (aspartate aminotransferase in case of
missing alanine aminotransferase) was dummy coded as normal or elevated (>50 U/L for
men;>35 U/L for women). One missing value was replaced by the sample mean.
We grouped comorbid psychiatric disorders following ICD-10 criteria as anxiety disorders
(F40, F41), somatoform disorders (F45), posttraumatic stress disorder (PTSD, F43.1), and eat-
ing disorders (F50). We noted the number of antidepressants, neuroleptics, pain medications
and anticonvulsants at hospital entry. These medications may point to illness severity and/or
interact with vitamin D metabolism.
Statistical analysis
Data were analyzed using PASW 18.0 statistical software package (SPSS Inc., Chicago, IL,
USA) with p-level< 0.05 (two-tailed). We first computed a principal component analysis
with oblimin rotation using standardized z-scores of all 34 items from the HADS-D, BDI-II,
and BSI-D to identify Bartlett factor scores for depressive symptoms with Eigenvalues> 1,
applying parallel analysis (Monte Carlo simulation) [32]. We then used multivariate analysis of
variance (MANOVA) and of covariance (MANCOVA) to compare the three vitamin D status
groups (deficiency, insufficiency, sufficiency) on scores of depressive symptom scales and fac-
tors, respectively, applying Roy's largest root. We defined covariates a priori, based on their
known associations with vitamin D deficiency and/or depression [5,12–15]; these were age,
sex, season, skin pigmentation, obesity, elevated levels of C-reactive protein and/or transami-
nases, anxiety disorders, PTSD, somatoform disorders, eating disorders, use of vitamin D
supplements, the number of antidepressants (0 vs. 1 vs. 2), neuroleptics (0 vs.1), and pain
medications (0 vs. 1 vs.2), use of anticonvulsants (yes/no), recurrent depressive episode, and
vitamin D assay technique. Pearson correlations quantified the bivariate association between
two continuous variables. Group differences for categorical variables were calculated with Pear-
son chi-square test or Fisher’s exact test. The effect sizes for the AN(C)OVAs were expressed as
eta-squared (η2) with values of 0.01, 0.06, and 0.14 indicating small, moderate, and large effects,
respectively [33]. Effect sizes for differences in mean values were expressed as Cohen's d, with
values of 0.2, 0.5, and 0.8 indicating small, moderate, and large effects, respectively [33].
Results
Participant characteristics
The study sample of 380 patients with a main diagnosis of an ICD-10 depressive episode was
middle aged (47.2±12.9 years) and comprised of about two-fold more women than men (69.5
vs. 30.5%). Psychiatric co-morbidity was substantial with an anxiety disorder in 24.7%, PTSD
in 7.4%, a somatoform disorder in 25.0%, and an eating disorder in 7.1%. Moreover, 32.6%
were obese. Two-fold as many patients suffered from a recurrent (F33) than from a first-time
(F32) depressive episode (65.0 vs. 35.0%). The current episode was mild in 21 (5.5%) cases
(F32.0, F33.0), moderate in 252 (66.3%) cases (F32.1, F33.1), severe in 82 (21.6%) cases (F32.2,
F33.2), and unspecified in 25 (6.6%) cases (F32.9, F33.9). Regarding comorbid physical medical
conditions, 19 patients had cardiovascular disease (ischemic heart disease, hypertensive heart
disease, peripheral vascular disease), one had hypertensive heart disease plus chronic kidney
disease, stage 3, and two had liver cirrhosis.
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Exploratory factor analysis for depressive symptoms
The mean ± SD value was 12.53 ± 4.35 (range 1–21) for the HADS-D, 30.48 ± 11.68 (range
3–58) for the BDI-II, and 11.57 ± 5.83 (range 0–24) for the BSI-D. The depressive symptom
scales correlated strongly with each other (all p-values<0.001): HADS-D and BDI-II: r = 0.73;
HADS-D and BSI-D: r = 0.68; and BDI-II and BSI-D: r = 0.84. There also was a correlation
between the BDI-II cognitive/affective and somatic/affective symptom subscales (r = 0.68,
p<0.001). Based on a HADS-D score8 and a BDI-II score14, clinically relevant depressive
symptoms were reported in 324 (85.3%) and 352 (92.6%) of patients, respectively.
The comprehensive principal component analysis using all 34 items from the HADS-D,
BDI-II and BSI-D revealed 36 factorial units to explain 100% of the variance by definition. Six
factorial units had an Eigenvalue>1. Parallel analysis yielded a solution with three factors to
be retained, together explaining 48.7% of the variance. Further inspection of the communalities
output showed four items (i.e., BDI-II #10/crying, BDI-II #11/agitation, BDI-II #16/changes in
sleeping pattern, BDI-II #18/changes in appetite) with correlations<0.30, indicating low fit
with the other items in the three factors. To improve the efficiency of the factor analysis, these
items were deleted to obtain a final three-factor solution that explained 52.8% of the variance.
For illustrative purposes, Table 1 shows the individual items from the three depressive symp-
tom scales with loadings>0.4 on the three factors termed "Negative Affect", "Anhedonia", and
"Inhibition". All factors were normally distributed and correlated moderately with each other
(all p-values<0.001): negative affect and anhedonia: r = 0.51; negative affect and inhibition:
r = 0.29; anhedonia and inhibition: r = 0.34.
Associations of vitamin D status with covariates
Table 2 shows that vitamin D status was significantly associated with season and the use of vita-
min D supplements and antidepressants. As expected, more patients with vitamin D deficiency
than with insufficient (p<0.001) or sufficient (p = 0.010) vitamin D were hospitalized during
the winter season. Patients with vitamin D deficiency used less frequently vitamin D containing
supplements than those with sufficient (p<0.001) or insufficient (p = 0.008) vitamin D.
Patients with sufficient vitamin D were prescribed a greater number of antidepressant medica-
tions than those with vitamin D deficiency (p = 0.004).
Vitamin D status and severity of depressive symptoms
Unadjusted models. There was a significant group effect for vitamin D status in the
MANOVA analysis with all three depressive symptom scales (F3,376 = 4.56, p = 0.004; η
2 =
0.035) and also in the MANOVA analysis with all three depressive symptom factor scores
(F3,376 = 4.85, p = 0.003; η
2 = 0.037) as the dependent variables. As shown in Table 3, there
were significant group differences in the HADS-D score (p = 0.006; η2 = 0.027), the BDI-II
total score (p = 0.044; η2 = 0.016), and the anhedonia factor score (p = 0.002; η2 = 0.034), but
not the BSI-D score, the negative affect factor score, and the inhibition factor score. Regarding
BDI-II subscales, there was a significant group difference for the somatic/affective symptom
score (p = 0.045; η2 = 0.016), but not for the cognitive/affective symptom score (p>0.09).
Post hoc analyses revealed that patients with vitamin D deficiency had greater levels of
HADS-D symptoms than those with vitamin D deficiency (p = 0.019, Cohen's d = 0.27) or suf-
ficiency (p = 0.007, d = 0.43). Likewise, BDI-II symptoms were higher in patients with vitamin
D deficiency compared to those with sufficient vitamin D (p = 0.014, d = 0.42) and the same
was observed for somatic/affective symptoms (p = 0.019; d = 0.40). Patients with vitamin D
deficiency also scored higher on the anhedonia factor than those with insufficient (p = 0.005,
d = 0.32) or sufficient (p = 0.004, d = 0.47) vitamin D.
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Fully adjusted models. The significance of the results from the MANOVA analyses was
maintained in the fully adjusted MANCOVA analyses. After controlling for all covariates,
there were significant group effects for vitamin D status for depressive symptom scales (F3,358 =
4.41, p = 0.005; η2 = 0.036) and factor scores (F3,358 = 4.47, p = 0.004; η
2 = 0.036).
As shown in Table 3, the three groups significantly differed in the HADS-D score
(p = 0.010; η2 = 0.025), the BDI-II total score (p = 0.023; η2 = 0.021), and the anhedonia factor
score (p = 0.003; η2 = 0.032), but not the BSI-D score, the negative affect factor score, and the
inhibition factor score. Regarding BDI-II subscales, there was a significant group difference for
the cognitive/affective symptom score (p = 0.018; η2 = 0.022), but not for the somatic/affective
symptom score (p>0.08).
Again, post hoc analyses revealed that patients with vitamin D deficiency had greater levels
of HADS-D symptoms than those with vitamin D insufficiency (p = 0.023) or sufficiency
(p = 0.008); BDI-II total symptoms were also higher in patients with vitamin D deficiency
Table 1. Summary of the rotated three-factor solution with item loadings.
Scale/item Content Factor 1 Factor 2 Factor 3
Negative affect Anhedonia Inhibition
BDI-II #7 c/a Self-dislike 0.794
BDI-II #3 c/a Sense of failure 0.785
BDI-II #8 c/a Self-accusations 0.783
BSI #50 Feelings of worthlessness 0.773
BDI-II #5 c/a Guilty feelings 0.771
BDI-II #14 c/a Worthlessness 0.721
BDI-II #6 c/a Punishment feelings 0.621
BSI #35 Feeling hopeless about the future 0.588
BDI-II #9 c/a Suicidal thoughts or wishes 0.569
BSI #9 Thoughts about ending your life 0.552
BSI #16 Feeling lonely 0.515
BDI-II #2 c/a Feling discouraged about the future 0.477
BDI-II #17 s/a Irritability 0.401
HADS #2 Enjoy the things I used to enjoy 0.861
HADS #4 Can laugh and see the funny things of life 0.832
HADS #14 Can enjoy a good book/radio/Tv program 0.742
BDI-II #4 c/a Loss of pleasure 0.700
HADS #6 Feel cheerful 0.673
BDI-II #12 c/a Loss of interest 0.595
BSI #18 Feeling no interest in things 0.499
HADS #12 Look forward with enjoyment to things 0.488
HADS #10 Lost interest in my appearance 0.442
BDI-II #1 c/a Feeling sad 0.437
BDI-II #21 s/a Loss of interest in sex 0.412
BDI-II #20 s/a Tiredness or fatigue 0.726
BDI-II #15 s/a Loss of energy 0.616
BDI-II #19 s/a Concentration difﬁculty 0.520
HADS #8 Slowed down 0.511
Only item loadings >0.4 are shown. BDI-II, Beck Depression Inventory-II (c/a, cognitive/affective item; s/a, somatic/affective item); BSI, Brief Symptom
Inventory; HADS, Hospital Anxiety and Depression Scale
doi:10.1371/journal.pone.0138550.t001
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compared to those with sufficient vitamin D (p = 0.007). Compared to patients with sufficient
vitamin D, those with vitamin D deficiency (p = 0.005) and also those with vitamin D insuffi-
ciency (p = 0.041) had higher levels of cognitive/affective symptoms. Moreover, patients with
vitamin D deficiency scored higher on the anhedonia factor than those with insufficient
(p = 0.005) or sufficient (p = 0.005) vitamin D.
Several covariates showed a significant and independent association with depressive symp-
tom scales and factor scores in the fully adjusted models (p-values<0.05; S1 Table).
Supplementary multivariate analyses. In an attempt to corroborate the above multivari-
ate results, we performed three complementary analyses. Firstly, numerous physical medical
conditions have been associated with both depression and low vitamin D levels and thus might
confound the observed relationships. However, the significance of the relationship between
vitamin D status and depressive symptomatology did not change with additional adjustment
for the 22 patients with a comorbid cardiovascular, renal, or kidney disease. Secondly, over-
weight (not only obesity) has also been associated with low vitamin D levels. The significance
of the relation between vitamin D status and depressive symptomatology was maintained,
when controlling for overweight (BMI25 kg/m2 vs. BMI< 25 kg/m2) instead of obesity
(except for somatic/affective symptoms which turned out to be similar in patients with
Table 2. Associations between vitamin D status and covariates in 380 patients.
Variables Deﬁciency Insufﬁciency Sufﬁciency P-value
25-OH D <50 nmol/l 25-OH D = 50–75 nmol/l 25-OH D > 75 nmol/l
n = 211, 55.5% n = 121, 31.8% n = 48, 12.6%
Age (yrs) 47.53 ± 13.50 47.10 ± 12.27 46.01 ± 12.08 0.761
Female sex, n (%) 142 (67.3) 88 (72.7) 34 (70.8) 0.572
Winter season, n (%) 118 (55.9) 41 (33.9) 17 (35.4) <0.001
Dark skin pigmentation, n (%) 48 (22.7) 19 (15.7) 9 (18.8) 0.295
Obesity, n (%) 77 (36.5) 37 (30.6) 10 (20.8) 0.095
Elevated liver enzymes, n (%) 21 (10.0) 12 (9.9) 5 (10.4) 1.000
Elevated CRP, n (%) 38 (18.0) 19 (15.7) 5 (10.4) 0.427
Anxiety disorder, n (%) 57 (27.0) 30 (24.8) 7 (14.6) 0.197
PTSD, n (%) 19 (9) 7 (5.8) 2 (4.2) 0.461
Somatoform disorder, n (%) 55 (26.1) 27 (22.3) 13 (27.1) 0.703
Eating disorder, n (%) 10 (4.7) 11 (9.1) 6 (12.5) 0.093
Vitamin D supplement, n (%) 14 (6.6) 19 (15.7) 12 (25.0) 0.001
Antidepressants
No antidepressants 63 (29.9) 27 (22.3) 15 (31.3) 0.009
1 antidepressant 118 (55.9) 67 (55.4) 17 (35.4)
2 antidepressants 30 (14.2) 27 (22.3) 16 (33.3)
Neuroleptic use, n (%) 48 (22.7) 28 (23.1) 10 (20.8) 0.947
Anticonvulsant use, n (%) 31 (14.7) 16 (13.2) 11 (22.9) 0.270
Pain medications
No pain medications 110 (52.1) 67 (55.4) 28 (58.3) 0.507
1 pain medication 66 (31.1) 42 (34.7) 14 (29.2)
 2 pain medications 35 (16.6) 12 (9.9) 6 (12.5)
Recurrent depression, n (%) 132 (62.6) 84 (69.4) 31 (64.6) 0.450
Values are means±SD or absolute numbers (percentages). CRP, C-reactive protein; PTSD, posttraumatic stress disorder
doi:10.1371/journal.pone.0138550.t002
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insufficient and sufficient vitamin D). Thirdly, the fact that two assay methods were used to
assess 25-OH D could be a confounding factor even when controlling for a dummy coded vari-
able. An interaction term “vitamin D status-by-assay method” was not significant, supporting
the notion that results were not evidently affected by the use of two different 25-OH D assays.
Discussion
We found that vitamin D deficiency was significantly associated with increased levels of
depressive symptoms in patients hospitalized with a depressive episode. To our knowledge,
Table 3. Vitamin D status and unadjusted and adjusted levels of depressive symptoms.
Depressive symptomatology Deﬁciency Insufﬁciency Sufﬁciency P-value
25-OH D <50 nmol/l 25-OH D = 50–75 nmol/l 25-OH D > 75 nmol/l
n = 211, 55.5% n = 121, 31.8% n = 48, 12.6%
HADS-D scores
Unadjusted mean ± SD 13.13 ± 4.23 1,2 11.98 ± 4.33 11.27 ± 4.47 0.006
Fully adjusted mean ± SEM 13.12 ± 0.29 1,2 12.00± 0.38 11.28 ± 0.61 0.010
BDI-II scores
Total scores
Unadjusted mean ± SD 31.51 ±11.86 2 30.10 ±11.75 26.92 ±10.04 0.044
Fully adjusted mean ± SEM 31.67 ± 0.77 2 29.90 ±1.01 26.70 ± 1.62 0.023
Cognitive/affective scores
Unadjusted mean ± SD 11.86 ± 0.42 11.51 ± 0.56 9.73 ± 0.89 0.095
Fully adjusted mean ± SEM 12.04 ± 0.39 2 11.33 ± 0.51 3 9.39 ± 0.82 0.018
Somatic affective scores
Unadjusted mean ± SD 19.65 ± 0.45 2 18.59 ±0.59 17.19 ± 0.94 0.045
Fully adjusted mean ± SEM 19.63 ± 0.45 18.57 ± 0.59 17.32 ± 0.95 0.078
BSI-D scores
Unadjusted mean ± SD 11.84 ± 5.92 11.43 ±5.89 10.69 ± 5.22 0.442
Fully adjusted mean ± SEM 11.88 ± 0.39 11.34 ± 0.50 10.74 ± 0.81 0.422
Negative affect factor scores
Unadjusted mean ± SD 0.034 ± 1.032 0.022 ± 0.956 -0.203 ± 0.957 0.321
Fully adjusted mean ± SEM 0.058 ± 0.064 -0.005 ± 0.083 -0.243 ± 0.13 0.140
Anhedonia factor scores
Unadjusted mean ± SD 0.160 ± 0.978 1,2 -0.160 ±0.997 -0.300 ± 0.992 0.002
Fully adjusted mean ± SEM 0.155 ± 0.066 1,2 -0.157 ± 0.086 -0.288 ± 0.137 0.003
Inhibition factor scores
Unadjusted mean ± SD 0.024 ± 1.004 0.010 ± 1.000 -0.128 ± 0.993 0.633
Fully adjusted mean ± SEM 0.002 ± 0.071 0.027 ± 0.093 -0.076 ± 0.149 0.837
Group comparisons were calculated with multivariate analysis of variance (unadjusted) or covariance with full adjustment for age, sex, season, skin
pigmentation, obesity, elevated liver enzyme levels, elevated C-reactive protein levels, psychiatric comorbidity (anxiety disorder, posttraumatic stress
disorder, somatoform disorder, eating disorder), recurrent depressive episode, medication (vitamin D supplements, number of antidepressants, use of
neuroleptics, use of anticonvulsants, number of pain medications), and vitamin D assay.
1 signiﬁcantly higher with vitamin D deﬁciency than vitamin D insufﬁciency.
2 signiﬁcantly higher with vitamin D deﬁciency than vitamin D sufﬁciency.
3 signiﬁcantly higher with vitamin D insufﬁciency than with vitamin D sufﬁciency.
BDI-II, Beck Depression Inventory-II; BSI-D, depression subscale of the Brief Symptom Inventory; HADS-D, depression subscale of the Hospital Anxiety
and Depression Scale.
doi:10.1371/journal.pone.0138550.t003
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this is the first study investigating a relation between vitamin D deficiency and a psychiatric
diagnosis of depression in hospitalized patients. The findings may be important because the
measurement of vitamin D levels has increasingly become routine in clinical psychiatry with
the hope to offer a new therapeutic option for depression [34]. Significant functional
impairment having compromised outpatient therapy was a premise for our patients to be hos-
pitalized. Therefore, hospitalized patients are in particular need of multicomponent antidepres-
sant therapy, making vitamin D a potentially attractive adjunct to established therapies such as
antidepressant medication [7].
In terms of good clinical practice for vitamin D substitution in depression, the current litera-
ture suggests that vitamin D substitution will only benefit individuals who a) have clinically rel-
evant depressive symptoms [16], b) are vitamin D deficient based on measured 25-OH D levels
and c) will also increase their 25-OH D levels [6]. In other words, too low amounts of vitamin
D (<800 I.U. daily) in those with vitamin D deficiency, as well as vitamin D substitution in
those with sufficient vitamin D, will both be ineffective in depressed individuals [6]. Although
we did not study an effect of vitamin D on depressive mood, our findings support the notion
that, even in hospitalized clinically depressed patients, vitamin D deficiency is associated with
significantly more depressive symptoms than vitamin D sufficiency after controlling for impor-
tant covariates of 25-OH D levels and depression. This difference seemed considerably robust,
as it was observed for both the HADS-D and BDI-II total scores. Importantly, the HADS-D
excludes somatic/affective symptoms of depression, and our analysis on BDI-II subscales
revealed vitamin D deficiency to be significantly related to cognitive/affective symptoms but
not somatic/affective ones. Therefore, vitamin D deficiency could particularly be associated
with cognitive/affective symptoms of depression, but less so with somatic/affective ones. In
terms of HADS-D scores, patients with deficient vitamin D also had more depressive symp-
toms than those with insufficient vitamin D with, although the latter group did not differ from
those with sufficient vitamin D. Somewhat different from these post hoc findings, BDI-II cog-
nitive/affective symptom scores were higher in patients with insufficient versus sufficient vita-
min D but similar in those with deficient and insufficient vitamin D. The effects sizes of the
above observations were small-to-moderate, and, thus, of clinical relevance. We thus interpret
that vitamin deficiency (25-OH D levels<50 nmol/l) may warrant particular clinical attention
in patients hospitalized with psychiatric depression. Although this can be assumed, random-
ized controlled trials are needed to show that depressive symptoms can indeed be lowered in
these patients through vitamin D supplementation above and beyond standard antidepressant
treatment.
As a novel aspect of our study, we performed a principal component analysis on depressive
symptom items from three validated and widely used depression symptom scales. We found
that symptoms related to a factor reflecting “Anhedonia” were significantly increased in vita-
min deficient patients compared with those having insufficient or sufficient vitamin D. In
contrast, two other depressive symptom factors, we denoted with “Negative Affect” and “Inhi-
bition”, were unrelated to vitamin D deficiency. Anhedonia is a core symptom of a depressive
episode which refers to diminished pleasure from, or interest in, previously rewarding activi-
ties. A single infusion of the noncompetitive N-Methyl-D-aspartate receptor antagonist keta-
mine has recently been shown to rapidly improve symptoms of anhedonia in patients with
major depression and treatment-resistant bipolar disorder, with an effect lasting up to three
and 14 days, respectively [35,36]. Anti-hedonic effects of ketamine were mediated through
changes in metabolic activity in the dorsal anterior cingulate cortex, orbitofrontal cortex, puta-
men, and the hippocampus [35,36]. In agreement with a potential role of vitamin D in the neu-
robiology of anhedonia, vitamin D receptors have also been found in the hippocampus both in
the rodent and human brain [37,38]. Depressive/anhedonia-like behavior in rodents exposed
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to unpredictable chronic mild stress was associated with downregulated expression of the sero-
tonin transporter and upregulated expression of vitamin D receptors both in the hippocampus
[39,40]; this may suggest a compensatory mechanism through vitamin D signaling that pro-
tects from stress-induced effects on the brain resulting in anhedonia [39]. There is no approved
medication to improve anhedonia and standard treatments of depression do little to alleviate
symptoms of anhedonia [35,36]. Therefore, future randomized controlled trials may want to
particularly test for an effect of vitamin D supplementation on anhedonia symptoms.
We expectedly found that patients who were hospitalized during the winter season, and
those with a greater number of antidepressant medications, showed an increased frequency of
vitamin D deficiency, which, in turn was less frequent in those taking vitamin D supplements.
Controlling for these variables and for other potential confounders did not change the signifi-
cant relationship between vitamin D deficiency and depressive symptoms (except for the
somatic/affective symptom subscale of the BDI-II). Also, the relationship was not attenuated
with adjustment for covariates that were associated with increased levels of depressive symp-
toms, including demographic variables, psychiatric comorbidity, medication use, and recurrent
depression. This may suggest our findings on a role of vitamin D deficiency for depressive
symptoms can be generalized to hospitalized patients with clinical depression who otherwise
are not uniform in population characteristics.
Strengths of the current study were the sample size, allowing us to compute factor analysis
with an ample number of items from three validated depression questionnaires, and the assess-
ment of psychiatric diagnoses with standardized criteria in hospitalized patients. Limitations
included the observational design with retrospectively collected data. Specifically, because the
selection of study participants after measuring vitamin D may not be random, we cannot rule
out a selection bias. During the study period, the knowledge of a potentially important role of
vitamin D for mental health has been accumulating, so all medical staff was increasingly
advised to routinely order 25-OH D levels at hospital entry. However, before this was fully
implemented, 25-OH Dmay have been measured based on risk factors, making those included
in the study different from those excluded. We were unable to obtain information on several
variables that may affect depression and vitamin D levels, so residual confounding cannot be
excluded. Specifically, we were unable to adjust our analyses for physical activity (both indoors
and outdoors), sun exposure and the use of sunscreen, as well as for dietary sources of vitamin
D. This lack of information is important in interpreting our data because patients with clinical
depression generally exhibit unhealthy behaviors, psychomotor retardation, and social with-
drawal, all of which might directly or indirectly influence 25-OH D levels. Additional control-
ling for important physical medical conditions did not alter our results in a supplementary
analysis. However, in a clinical sample as ours, it is impracticable to control for all the mental
and physical comorbidities which all can be associated with depression and low vitamin D lev-
els in their own right. We did not assess depressive symptoms by a clinical interview, although
the association of 25-OH D levels with depressive symptoms has been shown to be stronger
when depression was assessed by diagnostic interviews compared with self-reported symptom
scales [1]. Nevertheless, we applied validated psychometric instruments, such as the HADS-D,
with an ability to identify depression “caseness” with a sensitivity of 82% and a specificity of
74% when applying a cut-off score8 [41]. The method of vitamin D measurement changed
halfway through the study. This is unfortunate as commercially available 25-OH D assays
often show not the same accuracy to detect low vitamin D levels [42]. However, controlling for
the two assay methods and results from a supplementary moderator analysis suggested that
our findings were not evidently affected by using two assay methods, although we acknowledge
that some uncertainty remains regarding this methodological issue.
Vitamin D and Depressive Symptomatology
PLOS ONE | DOI:10.1371/journal.pone.0138550 September 23, 2015 12 / 15
Conclusions
This study showed that vitamin D deficiency at 25-OH D levels<50 nmol/l is significantly
associated with increased levels of depressive symptoms in patients hospitalized with psychiat-
ric depression. This finding was suggested to be robust and of clinical relevance with cognitive/
affective symptoms and particularly anhedonia symptoms being affected by vitamin D defi-
ciency. Based on previous knowledge, it might be prudent to supplement this patient popula-
tion with at least 800 I.U. daily of vitamin D. Whether those high in anhedonia will particularly
profit from such practice, is an important question to be examined in future intervention
studies.
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